Published in Pharmacogenomics on September 01, 2014
Advancing Pharmacogenomics as a Component of Precision Medicine: How, Where, and Who? Clin Pharmacol Ther (2015) 0.82
Preemptive Panel-Based Pharmacogenetic Testing: The Time is Now. Pharm Res (2017) 0.81
Introducing pharmacogenetic testing with clinical decision support into primary care: a feasibility study. CMAJ Open (2016) 0.78
Evaluation of a pharmacogenetic educational toolkit for community pharmacists. Pharmacogenomics (2016) 0.77
Precision Medicine at the University of Alabama at Birmingham: Laying the foundational processes through implementation of Genotype-Guided Antiplatelet Therapy. Clin Pharmacol Ther (2017) 0.76
Pharmacists should jump onto the clinical pharmacogenetics train. Am J Health Syst Pharm (2016) 0.75
Patient experiences with pharmacogenetic testing in a primary care setting. Pharmacogenomics (2016) 0.75
Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA (1998) 32.05
Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care (1986) 22.65
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol (1999) 11.78
SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med (2008) 11.31
Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res (1999) 9.85
The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med (2007) 9.48
Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med (2003) 7.23
Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) (2001) 4.88
Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med (2009) 3.44
The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol (2009) 3.10
A checklist for identifying determinants of practice: a systematic review and synthesis of frameworks and taxonomies of factors that prevent or enable improvements in healthcare professional practice. Implement Sci (2013) 3.00
Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation (2012) 2.98
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90
National Ambulatory Medical Care Survey: 2006 summary. Natl Health Stat Report (2008) 2.60
Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA (2001) 2.49
Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol (2008) 2.21
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics (2010) 2.19
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet (2005) 2.13
Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin Genet (2012) 2.07
Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf (2006) 2.01
Addressing the challenges of the clinical application of pharmacogenetic testing. Clin Pharmacol Ther (2009) 1.99
Assessing the economic impact of adverse drug effects. Pharmacoeconomics (2003) 1.85
Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm (2011) 1.85
Prescribing problems and pharmacist interventions in community practice. Med Care (1992) 1.78
Personalizing medicine with clinical pharmacogenetics. Genet Med (2011) 1.73
When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology (2009) 1.65
The potential impact of pharmacogenetic testing on medication adherence. Pharmacogenomics J (2013) 1.64
The clinical application of genetic testing in type 2 diabetes: a patient and physician survey. Diabetologia (2009) 1.63
Physicians' knowledge of genetics and genetic tests. Acad Med (1993) 1.62
Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet (2014) 1.57
Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians. J Gen Intern Med (2005) 1.54
Physician knowledge and attitudes towards molecular genetic (DNA) testing of their patients. Clin Genet (1998) 1.47
Genetic education for primary care providers: improving attitudes, knowledge, and confidence. Can Fam Physician (2009) 1.40
A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting. BMC Health Serv Res (2013) 1.38
Genetic educational needs and the role of genetics in primary care: a focus group study with multiple perspectives. BMC Fam Pract (2011) 1.37
Providing patients with pharmacogenetic test results affects adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial. Pharmacogenomics J (2013) 1.24
Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program. Am J Med Genet C Semin Med Genet (2014) 1.19
Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics (2010) 1.19
Insurance coverage policies for personalized medicine. J Pers Med (2012) 1.19
Facilitating clinical implementation of pharmacogenomics. JAMA (2011) 1.16
Physicians' preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. Genet Test Mol Biomarkers (2013) 1.15
Adverse drug reactions in United States hospitals. Pharmacotherapy (2006) 1.14
Trends in primary care antidepressant prescribing 1995-2007: a longitudinal population database analysis. Br J Gen Pract (2011) 1.13
Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer (2011) 1.10
Prioritization of future genetics education for general practitioners: a Delphi study. Genet Med (2012) 1.10
Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan. J Manag Care Pharm (2012) 1.08
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genet Med (2012) 1.03
Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants. Pharmacogenet Genomics (2005) 1.02
Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Res Treat (2012) 1.02
Defining the opportunity for pharmacogenetic intervention in primary care. Pharmacogenomics (2006) 0.97
Evaluation of a pharmacist-managed lipid clinic that uses point-of-care lipid testing. J Clin Lipidol (2010) 0.94
Cost-effectiveness analysis in pharmacogenomics. Pharmacogenomics (2010) 0.89
The impact of a genetics education program on physicians' knowledge and genetic counseling referral patterns. Med Teach (2007) 0.87
Comparison of delivery strategies for pharmacogenetic testing services. Pharmacogenet Genomics (2014) 0.87
Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer. Pharmacogenomics (2008) 0.87
Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer. Value Health (2013) 0.87
Sustained effects of online genetics education: a randomized controlled trial on oncogenetics. Eur J Hum Genet (2013) 0.84
Pharmacy benefit managers, pharmacies, and pharmacogenomic testing: prescription for progress? Sci Transl Med (2010) 0.84
Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention. Circ Cardiovasc Qual Outcomes (2013) 0.83
Just how feasible is pharmacogenetic testing in the primary healthcare setting? Pharmacogenomics (2012) 0.82
Effectiveness of oncogenetics training on general practitioners' consultation skills: a randomized controlled trial. Genet Med (2013) 0.82
Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia. Pharmacoeconomics (2013) 0.81
Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation. Am J Geriatr Pharmacother (2009) 0.80
On pharmacogenomics in pharmacy benefit management. Pharmacotherapy (2012) 0.79
Radiation therapy after breast reconstruction: outcomes, complications, and patient satisfaction. Radiol Med (2013) 0.79
Role of genetic factors in statins side-effects. Cardiovasc Hematol Disord Drug Targets (2012) 0.79
Theranostics in primary care: pharmacogenomics tests and beyond. Expert Rev Mol Diagn (2012) 0.77
The pharmacists' role in improving guideline compliance for thyroid function testing in patients with heart failure. J Pharm Pract (2011) 0.76
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
Retracted A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med (2006) 6.69
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe (2009) 4.55
What clinicians should know about the QT interval. JAMA (2003) 4.45
Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health (2009) 4.29
Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation (2006) 3.96
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
Two self-management interventions to improve hypertension control: a randomized trial. Ann Intern Med (2009) 3.13
The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol (2009) 3.10
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev (2013) 2.56
Gene expression signatures that predict radiation exposure in mice and humans. PLoS Med (2007) 2.38
Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet (2010) 2.34
An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med (2013) 2.23
High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Mol Syst Biol (2009) 2.21
The Biomedical Resource Ontology (BRO) to enable resource discovery in clinical and translational research. J Biomed Inform (2010) 2.10
Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic influenza a infection. PLoS Genet (2011) 2.10
Personalized medicine: progress and promise. Annu Rev Genomics Hum Genet (2011) 2.06
Integrating diagnostics and therapeutics: revolutionizing drug discovery and patient care. Drug Discov Today (2002) 2.05
H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One (2011) 2.02
Correlation of peripheral-blood gene expression with the extent of coronary artery stenosis. Circ Cardiovasc Genet (2008) 1.92
Genomic medicine: a decade of successes, challenges, and opportunities. Sci Transl Med (2013) 1.89
Embracing the complexity of genomic data for personalized medicine. Genome Res (2006) 1.75
What do international pharmacoeconomic guidelines say about economic data transferability? Value Health (2010) 1.74
Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures. Diagn Microbiol Infect Dis (2006) 1.72
Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69
Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. J Am Coll Cardiol (2013) 1.61
Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS (2004) 1.61
High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients. Hepatology (2011) 1.59
Genomic risk profiling: attitudes and use in personal and clinical care of primary care physicians who offer risk profiling. J Gen Intern Med (2011) 1.56
Minimally Invasive Versus Open Pancreaticoduodenectomy for Cancer: Practice Patterns and Short-term Outcomes Among 7061 Patients. Ann Surg (2015) 1.55
A multinational review of recent trends and reports in dementia caregiver burden. Alzheimer Dis Assoc Disord (2004) 1.55
Public knowledge of and attitudes toward genetics and genetic testing. Genet Test Mol Biomarkers (2013) 1.52
A national clinical decision support infrastructure to enable the widespread and consistent practice of genomic and personalized medicine. BMC Med Inform Decis Mak (2009) 1.49
A host-based RT-PCR gene expression signature to identify acute respiratory viral infection. Sci Transl Med (2013) 1.46
Gene expression patterns in peripheral blood correlate with the extent of coronary artery disease. PLoS One (2009) 1.45
Gene expression signatures of radiation response are specific, durable and accurate in mice and humans. PLoS One (2008) 1.44
Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation. Crit Care Med (2008) 1.41
Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect Control Hosp Epidemiol (2005) 1.38
A host transcriptional signature for presymptomatic detection of infection in humans exposed to influenza H1N1 or H3N2. PLoS One (2013) 1.37
Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients. BMC Med Genomics (2011) 1.37
Improving care transitions: current practice and future opportunities for pharmacists. Pharmacotherapy (2012) 1.35
The Personalized Medicine Coalition: goals and strategies. Am J Pharmacogenomics (2005) 1.32
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg (2014) 1.26
Can we close the income and wealth gap between specialists and primary care physicians? Health Aff (Millwood) (2010) 1.25
Targeted therapies for cancer 2004. Am J Clin Pathol (2004) 1.23
Staphylococcus aureus bacteremia in patients with prosthetic devices: costs and outcomes. Am J Med (2005) 1.23
Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J Clin Oncol (2010) 1.20
The long and winding road to warfarin pharmacogenetic testing. J Am Coll Cardiol (2010) 1.20
Transforming academic health centers for an uncertain future. N Engl J Med (2013) 1.20
Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis. PLoS Genet (2009) 1.20
Peripheral blood gene expression profiling for cardiovascular disease assessment. Genomic Med (2008) 1.18
Opening up to precompetitive collaboration. Sci Transl Med (2010) 1.18
Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet (2008) 1.17
Genomic medicine: genetic variation and its impact on the future of health care. Philos Trans R Soc Lond B Biol Sci (2005) 1.16
A framework to evaluate the economic impact of pharmacogenomics. Pharmacogenomics (2006) 1.15
Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study. PLoS Genet (2010) 1.11
Candida albicans and non-albicans bloodstream infections in adult and pediatric patients: comparison of mortality and costs. Pediatr Infect Dis J (2009) 1.09
Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C. Antivir Ther (2012) 1.09
Blood gene expression signatures predict invasive candidiasis. Sci Transl Med (2010) 1.08
Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients. Clin J Am Soc Nephrol (2008) 1.08
Development and validation of a primary care-based family health history and decision support program (MeTree). N C Med J (2013) 1.07
Predicting Viral Infection From High-Dimensional Biomarker Trajectories. J Am Stat Assoc (2011) 1.07
Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions: report of a national heart, lung, and blood institute working group. Circulation (2010) 1.07
The Measurement to Understand Reclassification of Disease of Cabarrus/Kannapolis (MURDOCK) Study Community Registry and Biorepository. Am J Transl Res (2012) 1.07
Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. Am J Cardiol (2009) 1.07
Gene expression analysis of cardiovascular diseases: novel insights into biology and clinical applications. J Am Coll Cardiol (2006) 1.06
Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. Int J Radiat Oncol Biol Phys (2012) 1.05
The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records. Am J Transl Res (2012) 1.05
Genomic Medicine: 'grand challenges' in the translation of genomics to human health. Eur J Hum Genet (2008) 1.04
Challenges in the phenotypic characterisation of patients in genetic studies of coronary artery disease. J Med Genet (2006) 1.02
Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. Am Heart J (2008) 1.02
Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank. Clin Ther (2009) 1.01
Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy. J Thromb Thrombolysis (2012) 1.00
Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: Findings from ASCEND-HF. Circ Heart Fail (2013) 1.00
Gene expression-based classifiers identify Staphylococcus aureus infection in mice and humans. PLoS One (2013) 0.99
Bayesian inference of the number of factors in gene-expression analysis: application to human virus challenge studies. BMC Bioinformatics (2010) 0.98
Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. J Natl Cancer Inst (2013) 0.98
Longitudinal analysis of leukocyte differentials in peripheral blood of patients with acute respiratory viral infections. J Clin Virol (2013) 0.97
Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol (2007) 0.96
Robotic thyroidectomy for cancer in the US: patterns of use and short-term outcomes. Ann Surg Oncol (2014) 0.96
Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections. Am J Infect Control (2010) 0.95
Proximal large bowel volvulus in children: 6 new cases and review of the literature. J Pediatr Surg (2012) 0.94
The path to personalized medicine. Curr Opin Chem Biol (2002) 0.94
Retraction: Genomic signatures to guide the use of chemotherapeutics. Nat Med (2011) 0.94
Variation in the type and frequency of postoperative invasive Staphylococcus aureus infections according to type of surgical procedure. Infect Control Hosp Epidemiol (2010) 0.93
Impact of gene variants on sex-specific regulation of human Scavenger receptor class B type 1 (SR-BI) expression in liver and association with lipid levels in a population-based study. BMC Med Genet (2010) 0.93
Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals. Antivir Ther (2013) 0.93
Organizational improvements to enhance modern clinical epidemiology. JAMA (2008) 0.92
Treatment patterns and costs associated with sessile colorectal polyps. Am J Gastroenterol (2002) 0.92
A phase III randomized three-arm trial of physical therapist delivered pain coping skills training for patients with total knee arthroplasty: the KASTPain protocol. BMC Musculoskelet Disord (2012) 0.91
Patient and primary care provider experience using a family health history collection, risk stratification, and clinical decision support tool: a type 2 hybrid controlled implementation-effectiveness trial. BMC Fam Pract (2013) 0.91
Relationship between clinical outcomes and vascular access type among hemodialysis patients with Staphylococcus aureus bacteremia. Clin J Am Soc Nephrol (2006) 0.90
Detection of viruses via statistical gene expression analysis. IEEE Trans Biomed Eng (2010) 0.90
Genomic analyses: a neonatology perspective. J Pediatr (2006) 0.90